| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX001 (ip) | median survival time | saline | 1.76 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.34 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.63 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 3.51 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 3.95 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.28 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.93 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 7.9 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.89 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 11.9 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 13.3 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 17.8 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 08/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 26.7 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 08/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 03/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 1.76 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 2.34 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 2.63 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 3.51 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 3.95 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 5.28 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 5.93 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 7.9 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 8.89 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 11.9 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 13.3 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 17.8 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 90; 09/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 00/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 26.7 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 07/10 animals surviving on day 5 |
| Q01DX001 (iv) | median survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 00/10 animals surviving on day 5 |
| Q01DX004 (ip) | median survival time | saline | 2.0 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 10 |
| Q01DX004 (ip) | median survival time | saline | 2.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 76; 08/08 animals surviving on day 11 |
| Q01DX004 (ip) | median survival time | saline | 3.0 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 10 |
| Q01DX004 (ip) | median survival time | saline | 3.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 76; 07/08 animals surviving on day 11 |
| Q03DX002 (ip) | median survival time | saline | 4.0 mg/kg/injection | 237.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 10 |
| Q03DX002 (ip) | median survival time | saline | 6.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/08 animals surviving on day 10 |
| Q04DX002 (iv) | median survival time | saline with Tween-80 | 0.96 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 85; 12/12 animals surviving on day 7 |
| Q04DX002 (iv) | median survival time | saline with Tween-80 | 1.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 85; 11/11 animals surviving on day 7 |
| Q04DX002 (iv) | median survival time | saline with Tween-80 | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 85; 11/11 animals surviving on day 7 |
| Q04DX002 (iv) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 85; 12/12 animals surviving on day 7 |
| Q04DX002 (iv) | median survival time | saline with Tween-80 | 6.5 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 85; 11/11 animals surviving on day 7 |
| Q04DX003 (ip) | median survival time | saline | 1.17 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.76 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.63 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.95 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.93 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.89 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 13.3 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 07/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 1.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 4.0 mg/kg/injection | 263.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | suspension in saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 1.17 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 1.76 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 2.63 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 3.95 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 5.93 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 8.89 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 09/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 13.3 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 10/10 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 90; 06/10 animals surviving on day 5 |
| Q04DX004 (iv) | median survival time | saline with Tween-80 | 1.8 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 108; 10/10 animals surviving on day 11 |
| Q04DX004 (iv) | median survival time | saline with Tween-80 | 2.7 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 108; 11/11 animals surviving on day 11 |
| Q04DX004 (iv) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 108; 10/10 animals surviving on day 11 |
| Q04DX004 (iv) | median survival time | saline with Tween-80 | 5.9 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 108; 10/10 animals surviving on day 11 |
| Q07DX003 (iv) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 70; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX003 (iv) | median survival time | saline with Tween-80 | 6.1 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 70; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX003 (iv) | median survival time | saline with Tween-80 | 9.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 70; 10/10 animals surviving on tox evaluation day (usually day 5) |